Track Journey Medical Corporation Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Journey Medical Corporation Common Stock DERM Open Journey Medical Corporation Common Stock in new tab

6.63 USD
EPS
-0.37
P/B
5.54
ROE
-36.62
Beta
1.04
Target Price
13.50 USD
Loading chart...
Key Metrics
Earnings dateMay 19, 2026
EPS-0.37
Book Value1.13
Price to Book5.54
Debt/Equity82.60
% Insiders32.306%
Growth
Revenue Growth0.22%
Estimates
Forward P/E-104.17
Forward EPS-0.06
Target Mean Price13.50

DCF Valuation

Tweak assumptions to recompute fair value for Journey Medical Corporation Common Stock (DERM)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Journey Medical Corporation Common Stock Logo Journey Medical Corporation Common Stock Analysis (DERM)

United States Health Care Official Website Stock

Is Journey Medical Corporation Common Stock a good investment? Journey Medical Corporation Common Stock (DERM) is currently trading at 6.63 USD. Market analysts have a consensus price target of 13.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Journey Medical Corporation Common Stock is expected to release its next earnings report on May 19, 2026. The market consensus estimate for Forward EPS is -0.06.

Investor FAQ

Does Journey Medical Corporation Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Journey Medical Corporation Common Stock?

Journey Medical Corporation Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 19, 2026. The company currently has a trailing EPS of -0.37.

Company Profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Exchange Ticker
NMS (United States) DERM

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion